BioCentury
ARTICLE | Clinical News

VBL's VB-111 misses in Phase III for glioblastoma

March 9, 2018 6:58 PM UTC

Vascular Biogenics Ltd. (NASDAQ:VBLT) reported that ofranergene obadenovec (VB-111) missed the primary endpoint of improving overall survival (OS) in the Phase III GLOBE trial to treat recurrent glioblastoma.

The open-label, international trial enrolled about 252 patients to receive IV VB-111 every two months plus Avastin every two weeks or Avastin alone. VBL has an SPA from FDA for the trial...

BCIQ Company Profiles

Vascular Biogenics Ltd.